Evidence map›Paper›PMID 28724664›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2017

Biochemical, Molecular, and Clinical Characterization of Succinate Dehydrogenase Subunit A Variants of Unknown Significance.

Amber E Bannon, Jason Kent, Isaac Forquer, Ajia Town, Lillian R Klug, Kelly McCann, Carol Beadling, Oliver Harismendy, Jason K Sicklick, Christopher Corless and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Genes · 2023
    Review
  5. Review
  6. Frontiers in oncology · 2021
    Article
  7. Article
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Amber E BannonDepartment of Cell and Developmental Biology, Heinrich Lab, Oregon Health and Science University, Portland, Oregon. bannon@ohsu.edu.
Jason KentDepartment of Cell and Developmental Biology, Heinrich Lab, Oregon Health and Science University, Portland, Oregon.
Isaac ForquerPortland VA Medical Center and Oregon Health and Science University, Portland, Oregon.
Ajia TownHeinrich Lab, Oregon Health and Science University, Portland, Oregon.
Lillian R KlugDepartment of Cancer Biology, Heinrich Lab, Oregon Health and Science University, Portland, Oregon.
Kelly McCannDivision of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.
Carol BeadlingDepartment of Pathology, Oregon Health and Science University, Portland, Oregon.
Oliver HarismendyDivision of Biomedical Informatics, Department of Medicine, Moores UCSD Cancer Center, University of California San Diego, La Jolla, California.
Jason K SicklickDivision of Surgical Oncology, Department of Surgery, Moores UCSD Cancer Center, University of California San Diego, La Jolla, California.
Christopher CorlessDepartment of Pathology, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon.
Ujwal ShindeDepartment of Biochemistry and Molecular Biology, Oregon Health and Science University, Portland, Oregon.
Michael C HeinrichDepartments of Medicine and Cell, Developmental, and Cancer Biology, Portland VA Health Care System and OHSU Knight Cancer Institute, Portland, Oregon.

Funding

VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DIANE M SIMEONE · 1985 to 2026
$124.9M
Elucidating the molecular and contextual basis for IDLE ultralow risk lesions and the tumor immune microenvironment of high risk in situ and invasive breast cancersU01CA196406 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BOROWSKY, ALEXANDER D, ESSERMAN, LAURA J · 2015 to 2020
$5.8M
Novel Allosteric Kinase Inhibitors Target Imatinib-Resistant GISTK08CA168999 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SICKLICK, JASON KEITH · 2014 to 2018
$888k
In vivo detection and genome-wide location analysis of DNA-adductsR21CA177519 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HARISMENDY, OLIVIER, HOWELL, STEPHEN B · 2013 to 2015
$667k
Oregon Clinical and Translational Research InstituteTL1TR000129 · NCATS · OREGON HEALTH & SCIENCE UNIVERSITY · PI ELLISON, DAVID H · 2012 to 2015
$613k
Defining the Germline Genomic Landscape of a Novel GIST Multi-tumor SyndromeR21CA192072 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SICKLICK, JASON KEITH · 2016 to 2017
$399k
Regulation of oncogenic KIT by LMTK3I01BX000338 · VA · PORTLAND VA MEDICAL CENTER · PI HEINRICH, MICHAEL C · 2009 to 2019
–
BLRD VA I01 BX000338NCATS NIH HHS TL1 TR000129NCI NIH HHS K08 CA168999NCI NIH HHS P30 CA023100NCI NIH HHS R21 CA177519NCI NIH HHS R21 CA192072NCI NIH HHS U01 CA196406
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Early Detection of CancerElectron Transport Complex IIGene Expression Regulation, EnzymologicGene Expression Regulation, NeoplasticHumansMutationNeoplasmsSaccharomyces cerevisiaeSaccharomyces cerevisiae ProteinsSuccinate DehydrogenaseElectron Transport Complex IISaccharomyces cerevisiae ProteinsSDH1 protein, S cerevisiaeSDH2 protein, S cerevisiaeSDHA protein, humanSuccinate Dehydrogenase

Identifiers

PMID28724664
PMCPMC6011831

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.